01/10/02

200205908 7

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
18 October 2001 (18.10.2001)

PCT

(10) International Publication Number
WO 01/77093 A1

(51) International Patent Classification[7]: C07D 295/08, 207/26, C07C 229/12, A61K 31/40, 31/195

(21) International Application Number: PCT/IB01/00427

(22) International Filing Date: 19 March 2001 (19.03.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/267,198 7 April 2000 (07.04.2000) US

(71) Applicant *(for all designated States except US)*: **PFIZER PRODUCTS INC.** [US/US]; Eastern Point Road, Groton, CT 06340 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **DAY, Wesley, Warren** [US/US]; Pfizer Global Research & Development, Eastern Point Road, Groton, CT 06340 (US). **JOHNSON, Kim, Anne** [US/US]; Pfizer Global Research & Development, Eastern Point Road, Groton, CT 06340 (US). **PRAKASH, Chandra, Aggarwal** [US/US]; Pfizer Global Research & Development, Eastern Point Road, Groton, CT 06340 (US). **EGGLER, James, Frederick** [US/US]; Pfizer Global Research & Development, Eastern Point Road, Groton, CT 06340 (US).


(74) Agents: **LUMB, J., Trevor** et al.; Pfizer Inc., 235 East 42nd Street, New York, NY 10017 (US).

(81) Designated States *(national)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States *(regional)*: ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian

[Continued on next page]

(54) Title: ESTROGEN AGONIST/ANTAGONIST METABOLITES



(57) Abstract: This invention relates to compounds that are mammalian metabolites of (-)-cis-6-phenyl-5-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-5,6,7,8-tetrahydronaphthalene-2-ol. The compounds of the invention can be used as standards for analytical assays or as intermediates for the further chemical synthesis or biosynthesis of chemical entities. The invention also relates to pharmaceutical compositions for the treatment of disease and methods of treating disease.

WO 01/77093 A1

162162

ACTION